한글목차

mTOR(포유류 라파마이신 타겟) 억제제 시장은 2030년까지 90억 달러에 달할 전망입니다.

2023년에 72억 달러로 추정된 mTOR(포유류 라파마이신 타겟) 억제제 시장은 예측 기간 동안 복합 연간 성장률(CAGR) 3.1%로 성장하여 2030년에는 90억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 경구 투여는 복합 연간 성장률(CAGR) 2.9%로 성장을 지속하고, 분석 기간 종료 시 58억 달러에 달할 것으로 예측됩니다. 정맥내 투여 부문의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 3.4%로 추정됩니다.

미국 시장은 20억 달러로 추정, 중국은 복합 연간 성장률(CAGR) 6.0%로 성장할 것으로 예측됩니다.

미국의 mTOR(포유류 라파마이신 타겟) 억제제 시장은 2023년 20억 달러로 추정됩니다. 세계의 2위 경제대국인 중국은 2030년까지 18억 달러 규모에 이를 것으로 예측되며, 예측 기간 동안의 복합 연간 성장률(CAGR)은 6.0%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR)은 각각 1.0%와 2.3%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 1.6%로 성장할 것으로 예측됩니다.

주요 동향과 촉진요인

에베롤리무스와 템시롤리무스 등의 mTOR 억제제는 신경내분비 종양, 유방암, 신세포암 등 다양한 암의 치료에 높은 효과가 있는 것으로 증명되고 있으며, 그 채용이 가속되고 있습니다. 게다가 자가면역 질환이나 암에 걸리기 쉬운 노년 인구가 증가하고 있는 것도, 이러한 억제제 수요를 한층 더 가속시키고 있습니다. 장기 이식 영역에서 mTOR 억제제는 면역 억제에 중요한 역할을 하며, 장기 거부 반응의 예방과 이식 수술의 성공에 기여함으로써 그 용도와 시장 수요를 확대하고 있습니다.

종양의 진행을 억제하는 mTOR 억제제의 효능과 특정 세포 경로를 타겟으로 하는 그 능력에 의해 mTOR 억제제는 특히 종래의 치료법에서는 불충분한 암 치료제로서 확립되고 있습니다. 2040년까지 2,750만명 이상이 새롭게 암을 앓고 있는 것으로 추정되는 등 세계의서 암 유병률이 증가하고 있기 때문에 현대 종양학에서 mTOR 억제제가 중요한 역할 를 담당하는 것은 분명합니다. 또한, mTOR 억제제의 다용도는 다른 의료 분야에서도 연구되고 있으며, 루푸스 및 류마티스 관절염과 같은자가 면역 질환, 신경 퇴행성 질환 및 심지어 희귀질환에 대한 응용 가능성에 대한 조사가 진행 중입니다. 입니다. 이와 같이 다양한 치료 영역으로의 확대가 큰 투자와 관심을 불러 시장의 성장 전망을 높이고 있습니다.

북미는 mTOR 억제제 시장을 독점하고 있으며, 견고한 헬스케어 인프라, 높은 암 이환율, 고도의 치료 솔루션을 필요로 하는 고령화 사회에 지지되고 있습니다. 이 지역의 주도적인 역할은 제약 회사와 생명 공학 기업이 mTOR 억제제의 혁신과 개선에 중점을 둔 광범위한 R&D 활동으로 더욱 강력해졌습니다. mTORC1/mTORC2 듀얼 억제제나 특정 유전자 변화를 타겟으로 한 맞춤형 치료 전략 등 신규 억제제의 개발이 진행되고 있는 것이 시장을 전진시키게 됩니다. 이러한 진보는 보다 적은 부작용으로 치료 성적의 향상을 약속하는 것으로, mTOR 억제제의 세계의 임상에의 확산과 채용에 기여하고 있습니다.

조사 대상 기업 예(주목의 86사)

• Accord Healthcare, Inc.
• Actiza Pharmaceutical Private Limited
• Aetos Pharma Pvt., Ltd.
• Anant Pharmaceuticals Pvt Ltd.
• AstraZeneca PLC
• Biocon Limited
• Endo Pharmaceuticals, Inc.
• Globela Pharma Private Limited
• InvivoGen
• Novartis AG
• Pfizer Inc.
• PV Pharma Healthcare Pvt. Ltd
• Teva Pharmaceuticals USA, Inc
• Tokyo Chemical Industry Co., Ltd.(TCI)
• Viatris Inc.;

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 스페인
• 러시아
• 기타 유럽
• 아시아태평양
• 호주
• 인도
• 한국
• 기타 아시아태평양
• 라틴아메리카
• 아르헨티나
• 브라질
• 멕시코
• 기타 라틴아메리카
• 중동
• 이란
• 이스라엘
• 사우디아라비아
• 아랍에미리트(UAE)
• 기타 중동
• 아프리카

제4장 경쟁

영문목차

Global mTOR (Mammalian Target of Rapamycin) Inhibitors Market to Reach US$9.0 Billion by 2030

The global market for mTOR (Mammalian Target of Rapamycin) Inhibitors estimated at US$7.2 Billion in the year 2023, is expected to reach US$9.0 Billion by 2030, growing at a CAGR of 3.1% over the analysis period 2023-2030. Oral Administration, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$5.8 Billion by the end of the analysis period. Growth in the Intravenous Administration segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 6.0% CAGR

The mTOR (Mammalian Target of Rapamycin) Inhibitors market in the U.S. is estimated at US$2.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 6.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Key Trends and Drivers

The global mTOR inhibitors market is poised for significant growth, driven by the increasing demand for effective treatments for cancer, organ transplant procedures, and autoimmune diseases. mTOR inhibitors such as everolimus and temsirolimus have proven highly effective in treating various cancers, including neuroendocrine tumors, breast cancer, and renal cell carcinoma, which has fueled their adoption. Additionally, the rising geriatric population, more prone to autoimmune disorders and cancers, has further spurred demand for these inhibitors. In the realm of organ transplantation, mTOR inhibitors play a crucial role in immunosuppression, helping to prevent organ rejection and enhance the success of transplant procedures, thereby broadening their applications and market demand.

The effectiveness of mTOR inhibitors in restraining tumor progression and their ability to target specific cellular pathways have established them as valuable cancer treatments, particularly where traditional therapies fall short. The increasing prevalence of cancer worldwide, with estimates suggesting over 27.5 million new cases by 2040, underscores the critical role of mTOR inhibitors in contemporary oncology. Furthermore, the versatility of these inhibitors is being explored in other medical fields, with ongoing research into their potential applications in autoimmune diseases like lupus and rheumatoid arthritis, neurodegenerative disorders, and even rare diseases. This expansion into various therapeutic areas is drawing substantial investment and interest, enhancing the market's growth prospects.

North America dominates the mTOR inhibitor market, supported by a robust healthcare infrastructure, a high incidence of cancer, and an aging population that necessitates advanced therapeutic solutions. The region's leading role is further cemented by extensive research and development activities undertaken by pharmaceutical and biotechnology firms, focusing on innovating and improving mTOR inhibitors. The ongoing development of novel inhibitors, such as dual mTORC1/mTORC2 inhibitors and personalized treatment strategies targeting specific genetic alterations, is set to propel the market forward. These advancements promise enhanced treatment outcomes with fewer side effects, contributing to the broadening scope and adoption of mTOR inhibitors in clinical practice worldwide.

Select Competitors (Total 86 Featured) -

• Accord Healthcare, Inc.
• Actiza Pharmaceutical Private Limited
• Aetos Pharma Pvt., Ltd.
• Anant Pharmaceuticals Pvt Ltd.
• AstraZeneca PLC
• Biocon Limited
• Endo Pharmaceuticals, Inc.
• Globela Pharma Private Limited
• InvivoGen
• Novartis AG
• Pfizer Inc.
• PV Pharma Healthcare Pvt. Ltd
• Teva Pharmaceuticals USA, Inc
• Tokyo Chemical Industry Co., Ltd. (TCI)
• Viatris Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • mTOR (Mammalian Target of Rapamycin) Inhibitors - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Expanding Applications of mTOR Inhibitors Beyond Cancer Treatment
  • Enhancements in Drug Formulation and Delivery Techniques
  • Role of mTOR Inhibitors in Aging and Age-Related Diseases
  • Increasing Incidence of Cancer and the Demand for Effective Therapeutics
  • Collaborative Research for Novel mTOR Inhibitors in Rare Diseases
  • Regulatory Incentives for Orphan Drug Designation
  • Impact of Genetic Research on Targeted Cancer Therapies
  • Advances in Personalized Medicine and Biomarker Development
  • Technological Integration in Drug Screening and Patient Monitoring
  • Global Health Policy Shifts Affecting Drug Approval Processes
  • Impact of Patent Cliffs on Innovation and Competition
  • Cross-disciplinary Research Enhancing Understanding of mTOR Pathways
  • Funding Landscape for Cancer Research and Its Impact on Market Growth
  • Trends in Consumer Demand for Advanced Therapeutic Modalities
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World mTOR (Mammalian Target of Rapamycin) Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Intravenous Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Intravenous Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Intravenous Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Everolimus Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Everolimus Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Everolimus Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Temsirolimus Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Temsirolimus Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Temsirolimus Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Sirolimus Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Sirolimus Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Sirolimus Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Oncology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Oncology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Oncology Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Organ Transplantation Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Organ Transplantation Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Organ Transplantation Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Immunosuppressant Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Immunosuppressant Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Immunosuppressant Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • mTOR (Mammalian Target of Rapamycin) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: USA 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: USA 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: USA 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• JAPAN
  • mTOR (Mammalian Target of Rapamycin) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Japan 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• CHINA
  • mTOR (Mammalian Target of Rapamycin) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: China Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: China 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: China Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: China 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: China Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: China 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• EUROPE
  • mTOR (Mammalian Target of Rapamycin) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Europe 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• FRANCE
  • mTOR (Mammalian Target of Rapamycin) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: France Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: France 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: France Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: France 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: France Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: France 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• GERMANY
  • mTOR (Mammalian Target of Rapamycin) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Germany 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Italy 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • mTOR (Mammalian Target of Rapamycin) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: UK 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: UK 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: UK 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: Spain 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: Spain 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: Russia 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: Russia 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Rest of Europe 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Rest of Europe 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • mTOR (Mammalian Target of Rapamycin) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Asia-Pacific 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: Asia-Pacific 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• AUSTRALIA
  • mTOR (Mammalian Target of Rapamycin) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Australia 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Australia 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• INDIA
  • mTOR (Mammalian Target of Rapamycin) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: India Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: India 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: India Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: India 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: India Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: India 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: South Korea 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: South Korea 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • mTOR (Mammalian Target of Rapamycin) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: Latin America 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: Latin America 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Argentina 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Argentina 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 214: Brazil 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 217: Brazil 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 223: Mexico 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 226: Mexico 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 232: Rest of Latin America 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 235: Rest of Latin America 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • mTOR (Mammalian Target of Rapamycin) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 241: Middle East 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 244: Middle East 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 253: Iran 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 256: Iran 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 262: Israel 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 265: Israel 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 271: Saudi Arabia 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 274: Saudi Arabia 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 280: UAE 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 283: UAE 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 289: Rest of Middle East 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 292: Rest of Middle East 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030
• AFRICA
  • mTOR (Mammalian Target of Rapamycin) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Oral Administration and Intravenous Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 298: Africa 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Intravenous Administration for the Years 2014, 2024 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 301: Africa 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Drug Class - Percentage Breakdown of Value Sales for Everolimus Drugs, Temsirolimus Drugs and Sirolimus Drugs for the Years 2014, 2024 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for mTOR (Mammalian Target of Rapamycin) Inhibitors by Indication - Percentage Breakdown of Value Sales for Oncology Indication, Organ Transplantation Indication, Immunosuppressant Indication and Other Indications for the Years 2014, 2024 & 2030

IV. COMPETITION